The cell polarity PTK7 receptor acts as a modulator of the chemotherapeutic response in acute myeloid leukemia and impairs clinical outcome

Thomas Prebet, Anne Catherine Lhoumeau, Christine Arnoulet, Anaïs Aulas, Sylvie Marchetto, Stéphane Audebert, Francesca Puppo, Christian Chabannon, Danielle Sainty, Marie Josée Santoni, Michael Sebbagh, Virginia Summerour, Yannick Huon, Won Sik Shin, Seung Taek Lee, Benjamin Esterni, Norbert Vey, Jean Paul Borg

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

The pseudo tyrosine kinase receptor 7 (PTK7) is an orphan tyrosine kinase receptor assigned to the planar cell polarity pathway. It plays a major role during embryogenesis and epithelial tissue organization. Here we found that PTK7 is also expressed in normal myeloid progenitors and CD34+ CD38 - bone marrow cells in humans. We performed an immunophenotyping screen on more than 300 patients treated for hematologic malignancies. We demonstrated that PTK7 is expressed in acute myeloid leukemia (AML) and is mostly assigned to granulocytic lineage differentiation. Patients with PTK7-positive AML are more resistant to anthracycline-based frontline therapy with a significantly reduced leukemia-free survival in a multivariate analysis model. In vitro, expression of PTK7 in cultured leukemia cells promotes cell migration, cell survival, and resistance to anthracycline-induced apoptosis. The intracellular region of PTK7 is required for these effects. Furthermore, we efficiently sensitized primary AML blasts to anthracycline-mediated cell death using a recombinant soluble PTK7-Fc protein. We conclude that PTK7 is a planar cell polarity component expressed in the myeloid progenitor compartment that conveys promigratory and antiapoptotic signals into the cell and that represents an independent prognosis factor of survival in patients treated with induction chemotherapy.

Original languageEnglish
Pages (from-to)2315-2323
Number of pages9
JournalBlood
Volume116
Issue number13
DOIs
Publication statusPublished - 2010 Sep 30

Fingerprint

Cell Polarity
Receptor Protein-Tyrosine Kinases
Acute Myeloid Leukemia
Modulators
Anthracyclines
Leukemia
Cells
Immunophenotyping
Induction Chemotherapy
Orphaned Children
Chemotherapy
Survival
Cell death
Hematologic Neoplasms
Cellular Structures
Bone Marrow Cells
Embryonic Development
Cell Movement
Cultured Cells
Cell Survival

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Prebet, T., Lhoumeau, A. C., Arnoulet, C., Aulas, A., Marchetto, S., Audebert, S., ... Borg, J. P. (2010). The cell polarity PTK7 receptor acts as a modulator of the chemotherapeutic response in acute myeloid leukemia and impairs clinical outcome. Blood, 116(13), 2315-2323. https://doi.org/10.1182/blood-2010-01-262352
Prebet, Thomas ; Lhoumeau, Anne Catherine ; Arnoulet, Christine ; Aulas, Anaïs ; Marchetto, Sylvie ; Audebert, Stéphane ; Puppo, Francesca ; Chabannon, Christian ; Sainty, Danielle ; Santoni, Marie Josée ; Sebbagh, Michael ; Summerour, Virginia ; Huon, Yannick ; Shin, Won Sik ; Lee, Seung Taek ; Esterni, Benjamin ; Vey, Norbert ; Borg, Jean Paul. / The cell polarity PTK7 receptor acts as a modulator of the chemotherapeutic response in acute myeloid leukemia and impairs clinical outcome. In: Blood. 2010 ; Vol. 116, No. 13. pp. 2315-2323.
@article{c7f523106ba34ee18d300f2d58f3284c,
title = "The cell polarity PTK7 receptor acts as a modulator of the chemotherapeutic response in acute myeloid leukemia and impairs clinical outcome",
abstract = "The pseudo tyrosine kinase receptor 7 (PTK7) is an orphan tyrosine kinase receptor assigned to the planar cell polarity pathway. It plays a major role during embryogenesis and epithelial tissue organization. Here we found that PTK7 is also expressed in normal myeloid progenitors and CD34+ CD38 - bone marrow cells in humans. We performed an immunophenotyping screen on more than 300 patients treated for hematologic malignancies. We demonstrated that PTK7 is expressed in acute myeloid leukemia (AML) and is mostly assigned to granulocytic lineage differentiation. Patients with PTK7-positive AML are more resistant to anthracycline-based frontline therapy with a significantly reduced leukemia-free survival in a multivariate analysis model. In vitro, expression of PTK7 in cultured leukemia cells promotes cell migration, cell survival, and resistance to anthracycline-induced apoptosis. The intracellular region of PTK7 is required for these effects. Furthermore, we efficiently sensitized primary AML blasts to anthracycline-mediated cell death using a recombinant soluble PTK7-Fc protein. We conclude that PTK7 is a planar cell polarity component expressed in the myeloid progenitor compartment that conveys promigratory and antiapoptotic signals into the cell and that represents an independent prognosis factor of survival in patients treated with induction chemotherapy.",
author = "Thomas Prebet and Lhoumeau, {Anne Catherine} and Christine Arnoulet and Ana{\"i}s Aulas and Sylvie Marchetto and St{\'e}phane Audebert and Francesca Puppo and Christian Chabannon and Danielle Sainty and Santoni, {Marie Jos{\'e}e} and Michael Sebbagh and Virginia Summerour and Yannick Huon and Shin, {Won Sik} and Lee, {Seung Taek} and Benjamin Esterni and Norbert Vey and Borg, {Jean Paul}",
year = "2010",
month = "9",
day = "30",
doi = "10.1182/blood-2010-01-262352",
language = "English",
volume = "116",
pages = "2315--2323",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "13",

}

Prebet, T, Lhoumeau, AC, Arnoulet, C, Aulas, A, Marchetto, S, Audebert, S, Puppo, F, Chabannon, C, Sainty, D, Santoni, MJ, Sebbagh, M, Summerour, V, Huon, Y, Shin, WS, Lee, ST, Esterni, B, Vey, N & Borg, JP 2010, 'The cell polarity PTK7 receptor acts as a modulator of the chemotherapeutic response in acute myeloid leukemia and impairs clinical outcome', Blood, vol. 116, no. 13, pp. 2315-2323. https://doi.org/10.1182/blood-2010-01-262352

The cell polarity PTK7 receptor acts as a modulator of the chemotherapeutic response in acute myeloid leukemia and impairs clinical outcome. / Prebet, Thomas; Lhoumeau, Anne Catherine; Arnoulet, Christine; Aulas, Anaïs; Marchetto, Sylvie; Audebert, Stéphane; Puppo, Francesca; Chabannon, Christian; Sainty, Danielle; Santoni, Marie Josée; Sebbagh, Michael; Summerour, Virginia; Huon, Yannick; Shin, Won Sik; Lee, Seung Taek; Esterni, Benjamin; Vey, Norbert; Borg, Jean Paul.

In: Blood, Vol. 116, No. 13, 30.09.2010, p. 2315-2323.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The cell polarity PTK7 receptor acts as a modulator of the chemotherapeutic response in acute myeloid leukemia and impairs clinical outcome

AU - Prebet, Thomas

AU - Lhoumeau, Anne Catherine

AU - Arnoulet, Christine

AU - Aulas, Anaïs

AU - Marchetto, Sylvie

AU - Audebert, Stéphane

AU - Puppo, Francesca

AU - Chabannon, Christian

AU - Sainty, Danielle

AU - Santoni, Marie Josée

AU - Sebbagh, Michael

AU - Summerour, Virginia

AU - Huon, Yannick

AU - Shin, Won Sik

AU - Lee, Seung Taek

AU - Esterni, Benjamin

AU - Vey, Norbert

AU - Borg, Jean Paul

PY - 2010/9/30

Y1 - 2010/9/30

N2 - The pseudo tyrosine kinase receptor 7 (PTK7) is an orphan tyrosine kinase receptor assigned to the planar cell polarity pathway. It plays a major role during embryogenesis and epithelial tissue organization. Here we found that PTK7 is also expressed in normal myeloid progenitors and CD34+ CD38 - bone marrow cells in humans. We performed an immunophenotyping screen on more than 300 patients treated for hematologic malignancies. We demonstrated that PTK7 is expressed in acute myeloid leukemia (AML) and is mostly assigned to granulocytic lineage differentiation. Patients with PTK7-positive AML are more resistant to anthracycline-based frontline therapy with a significantly reduced leukemia-free survival in a multivariate analysis model. In vitro, expression of PTK7 in cultured leukemia cells promotes cell migration, cell survival, and resistance to anthracycline-induced apoptosis. The intracellular region of PTK7 is required for these effects. Furthermore, we efficiently sensitized primary AML blasts to anthracycline-mediated cell death using a recombinant soluble PTK7-Fc protein. We conclude that PTK7 is a planar cell polarity component expressed in the myeloid progenitor compartment that conveys promigratory and antiapoptotic signals into the cell and that represents an independent prognosis factor of survival in patients treated with induction chemotherapy.

AB - The pseudo tyrosine kinase receptor 7 (PTK7) is an orphan tyrosine kinase receptor assigned to the planar cell polarity pathway. It plays a major role during embryogenesis and epithelial tissue organization. Here we found that PTK7 is also expressed in normal myeloid progenitors and CD34+ CD38 - bone marrow cells in humans. We performed an immunophenotyping screen on more than 300 patients treated for hematologic malignancies. We demonstrated that PTK7 is expressed in acute myeloid leukemia (AML) and is mostly assigned to granulocytic lineage differentiation. Patients with PTK7-positive AML are more resistant to anthracycline-based frontline therapy with a significantly reduced leukemia-free survival in a multivariate analysis model. In vitro, expression of PTK7 in cultured leukemia cells promotes cell migration, cell survival, and resistance to anthracycline-induced apoptosis. The intracellular region of PTK7 is required for these effects. Furthermore, we efficiently sensitized primary AML blasts to anthracycline-mediated cell death using a recombinant soluble PTK7-Fc protein. We conclude that PTK7 is a planar cell polarity component expressed in the myeloid progenitor compartment that conveys promigratory and antiapoptotic signals into the cell and that represents an independent prognosis factor of survival in patients treated with induction chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=77957720988&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957720988&partnerID=8YFLogxK

U2 - 10.1182/blood-2010-01-262352

DO - 10.1182/blood-2010-01-262352

M3 - Article

C2 - 20558616

AN - SCOPUS:77957720988

VL - 116

SP - 2315

EP - 2323

JO - Blood

JF - Blood

SN - 0006-4971

IS - 13

ER -